Moutan Cortex polysaccharide ameliorates diabetic kidney disease via modulating gut microbiota dynamically in rats

Int J Biol Macromol. 2022 May 1:206:849-860. doi: 10.1016/j.ijbiomac.2022.03.077. Epub 2022 Mar 17.

Abstract

Growing evidence suggests that polysaccharides from traditional Chinese medicine positively affect diabetic kidney disease (DKD) mainly through modulating gut microbiota. Previously, we demonstrated that supplementation with the polysaccharide from Moutan Cortex (MC-Pa) alleviated DKD in rats. The study intends to investigate the dynamic modulation of MC-Pa on DKD from the gut microbiota perspective. The DKD rat model was induced by a high-fat and high-sugar diet combined with streptozotocin (STZ). The rats were then supplemented with MC-Pa (80 and 160 mg/kg BW) for 12 weeks. The results showed that MC-Pa administration relieved hyperglycemia and renal injury in DKD rats. MC-Pa also reconstructed gut microbiota, improved intestinal barrier function, reduced serum proinflammatory mediators, and elevated the short-chain fatty acid (SCFAs) contents. In addition, the dynamics of Lactobacillus and Muribaculaceae_unclassified were in a dose- and time-dependent manner. Spearman correlation analysis found that a cluster of gut microbiota phyla and genera were significantly associated with DKD-related indicators. These results demonstrated that MC-Pa positively affected DKD rats by modulating gut microbiota dynamically and had potential as a prebiotic.

Keywords: Diabetic kidney disease; Gut microbiota; Moutan Cortex polysaccharide.

MeSH terms

  • Animals
  • Diabetes Mellitus*
  • Diabetic Nephropathies* / drug therapy
  • Dietary Carbohydrates
  • Drugs, Chinese Herbal
  • Gastrointestinal Microbiome*
  • Paeonia*
  • Polysaccharides / pharmacology
  • Polysaccharides / therapeutic use
  • Rats

Substances

  • Dietary Carbohydrates
  • Drugs, Chinese Herbal
  • Polysaccharides
  • moutan cortex